China's Burning Rock Biotech Q1 revenue falls on lower test volumes

Burning Rock Biotech

09/06/2026 11:49

Overview
China precision oncology NGS firm's Q1 revenue fell yr/yr on lower test volumes
Gross profit and non-GAAP gross margin declined from prior year
Operating expenses dropped 14% due to cost controls, but net loss widened yr/yr

Outlook
Company did not provide specific guidance or outlook for the current or future periods in press release

Result Drivers
CENTRAL LAB TEST VOLUME - Central laboratory revenue fell 15% yr/yr, mainly due to fewer tests as co continued transition to in-hospital testing
IN-HOSPITAL ONE-OFF - In-hospital revenue declined 8.5% yr/yr, mainly due to a one-off issue at two hospitals; excluding these, in-hospital revenue would have risen 2%
PHARMA R&D SLOWDOWN - Pharma research and development revenue dropped yr/yr, attributed to fewer testing services for pharma customers and lower milestone progress due to project timing

Company press release: ID:nGNXbZm7Jj

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
RMB 107.90 mln
 
Q1 EPS
 
-RMB 0.17
 
Q1 Net Income
 
-RMB 17.50 mln
 
Q1 Adjusted Gross Margin
 
74.60%
 
Q1 Gross Profit
 
RMB 78 mln
 
Q1 Operating Expenses
 
RMB 96.90 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)